HER2 positive breast carcinoma

This early-stage trial tests a new vaccine called ES2B-C001, with or without an immune booster (adjuvant), in 40 people with HER2-positive metastatic breast cancer who have already tried other treatments. The vaccine is designed to help the body's immune system recognize and atta…

This Phase 3 study tests whether adding the targeted drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can help people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation) live longer without their cancer growing…

This early-phase study tests the safety of giving specially grown immune cells (T cells) to people with metastatic HER2-positive breast cancer. Participants first receive a vaccine made from their own immune cells plus two drugs (pepinemab and trastuzumab) to help the body fight …

This early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This phase 4 study is testing the safety of trastuzumab deruxtecan, a targeted antibody-drug combination, in 100 Indian adults with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Participants have already received at least one prior anti-HER…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This phase 2 trial tests whether adding tucatinib to standard drugs trastuzumab and capecitabine can shrink tumors in people with advanced HER2+ breast cancer who have already tried several treatments. About 66 participants will receive the three-drug combination. The main goal i…

Researchers are reviewing medical records to see how well pyrotinib works and how safe it is in people with HER2-positive advanced breast cancer whose disease worsened after treatment with trastuzumab and pertuzumab. The study includes about 200 patients in China who received pyr…

This phase 3 trial tests a new drug called SHR-A1811, given alone or with pertuzumab, against the standard treatment (trastuzumab, pertuzumab, and docetaxel) in 868 women with HER2-positive breast cancer that has returned or spread. The goal is to see if the new approach can dela…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This Phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (Kadcyla) can prevent breast cancer from returning in people with high-risk HER2-positive breast cancer. About 1,188 participants who still had cancer af…

This study tests whether certain women with early-stage HER2-positive breast cancer can be treated with a targeted drug combination (PHESGO™) without chemotherapy. Researchers use specific markers to select patients whose tumors are highly dependent on the HER2 pathway. The goal …

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This early-stage trial tests an experimental oral drug called ZN-A-1041, alone or with other cancer drugs, in people with HER2-positive advanced solid tumors (including breast cancer that has spread to the brain). The study aims to find safe doses and check how the drug works in …

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …

This trial is testing whether combining the targeted drug trastuzumab with either oral chemotherapy or hormone therapy can effectively treat stage I HER2-positive breast cancer. The study includes women aged 18-70 with small, lymph-node-negative tumors, divided into two groups ba…

This phase III trial is testing whether the drug pyrotinib can further reduce the risk of breast cancer returning in women with HER2-positive early or locally advanced breast cancer who have already completed standard treatment with trastuzumab. Participants will be randomly assi…

This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…

This phase 3 trial is testing whether the drug trastuzumab deruxtecan (T-DXd), alone or with other chemotherapy drugs, works better than standard treatment before surgery in people with high-risk HER2-positive early breast cancer. About 927 participants will receive one of three …

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This study looks at whether people with HER2-positive metastatic breast cancer who have had their cancer controlled for at least three years can safely stop their anti-HER2 therapy. About 82 participants will either stop or continue treatment to see if the cancer stays away for a…

This study tests a new drug called trastuzumab deruxtecan (T-DXd), given alone or with another drug (pertuzumab), against the current standard treatment for HER2-positive breast cancer that has spread. About 1,157 people with this type of cancer will take part. The goal is to see…

This phase 3 trial is testing a new drug called SHR-A1811 against a standard chemotherapy combination for women with early-stage or locally advanced HER2-positive breast cancer. About 740 participants will receive either the new drug or standard treatment before surgery. The main…

This study tests a new drug called BL-M07D1, alone or combined with other medicines, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if these treatments shrink tumors and how safe they are. About 83 a…

This study tests whether adding tucatinib (a targeted pill) to standard T-DM1 therapy works better than T-DM1 alone for people with advanced HER2-positive breast cancer that has spread or can't be removed surgically. About 466 participants will receive either tucatinib or a place…

This phase 3 trial is comparing an experimental drug, BL-M07D1, against the approved therapy T-DM1 in people with advanced HER2-positive breast cancer that has not responded to previous treatments. The study aims to see whether BL-M07D1 can delay cancer progression better than T-…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This Phase 3 trial tests whether adding tucatinib (a targeted pill) to standard therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2+ breast cancer. About 654 participants with inoperable or metastatic disease will receive either tucatinib or …

This phase 2 trial tests whether adding immune-boosting drugs (avelumab and utomilumab) to standard chemotherapy and targeted therapy can help people with HER2-positive metastatic breast cancer whose disease has worsened after prior treatments. Participants are randomly assigned …

This study tests whether a new drug called RPH-051 works as well as the approved drug Perjeta when both are given with standard chemotherapy and another targeted therapy for people with HER2-positive breast cancer that has spread or cannot be removed. About 246 participants will …

This Phase 2 trial is testing whether a combination of three drugs—tucatinib, eribulin, and trastuzumab—is safe and effective for people with advanced HER2+ breast cancer that has not responded to prior treatments. The study will enroll 30 participants and measure tumor shrinkage…

This trial investigates whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and HER2-targeted drugs can destroy more cancer before surgery in people with HER2-positive breast cancer. Participants receive one of three treatment combinations befo…

This phase 3 trial compares a new drug combination (KN026 plus HB1801, with or without carboplatin) against the standard treatment (trastuzumab, pertuzumab, and docetaxel, with or without carboplatin) in people with early or locally advanced HER2-positive breast cancer. The goal …

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This phase 2 trial is testing how well older adults (60+) with advanced HER2+ breast cancer tolerate a combination of two targeted drugs: lapatinib and trastuzumab. The study enrolled 40 participants and focuses on side effects, especially heart-related issues and severe toxiciti…

This phase III trial tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone at preventing breast cancer from coming back. It involves over 1,000 patients with HER2-positive breast cancer who still have cancer cells after initial treatment. The stud…

This study looks at whether patients with early-stage HER2-positive breast cancer who have a complete response to initial chemotherapy and HER2-targeted therapy can safely receive only 6 months of further HER2 treatment instead of the standard 12 months. The goal is to reduce hea…

This early-phase trial tests whether a DNA vaccine made from a rat HER2 gene can safely stimulate the immune system in people with advanced or high-risk HER2-positive breast cancer. Thirteen participants receive multiple injections of the vaccine at different doses. The main goal…

This study tests whether radiation therapy followed by injecting two targeted antibodies (trastuzumab and pertuzumab) directly into the spinal fluid is safe and improves survival for people with HER2+ breast cancer that has spread to the lining of the brain and spine. About 33 pa…

This phase 2 trial is testing whether adding the immunotherapy drug atezolizumab to a standard combination of chemotherapy (paclitaxel) and two targeted drugs (trastuzumab and pertuzumab) is safe and effective for people with advanced HER2-positive breast cancer that has spread. …

This study tests a drug called T-DM1 in older adults (age 60+) with HER2-positive breast cancer after surgery. The goal is to see if it can prevent the cancer from coming back. About 111 participants received the drug, and researchers are tracking how long they stay cancer-free.

This study tests a newer targeted therapy, trastuzumab deruxtecan (T-DXd), against an older one, trastuzumab emtansine (T-DM1), in about 1,600 people with high-risk HER2-positive breast cancer who still have cancer after initial treatment. The goal is to see if T-DXd can better p…

This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab, with or without fulvestrant) for HER2-positive breast cancer. In the first part, it looks at safety in patients whose cancer has spread. In the second part, it compares these drugs to standard c…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This phase 2 trial is testing whether a combination of targeted cancer drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer without traditional chemotherapy. About 393 patients will receive these drugs as a subcutaneous injection, wit…

This Phase III trial is testing whether women and men with early-stage, low-risk HER2-positive breast cancer can safely skip radiation after breast-conserving surgery if they continue HER2-targeted therapy. About 1,300 participants are randomly assigned to receive either standard…

This phase 2 trial tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. First, patients receive a strong drug called trastuzumab deruxtecan (T-DXd) to shrink the cancer. Then, they switch to a maintenance therapy …

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to two standard targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in people with HER2-enriched breast cancer. The study involves 51 participants and measures how many have no or…

This study tests whether giving two targeted drugs, T-DM1 and pertuzumab, before surgery can completely eliminate early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the drugs for 18 weeks, then undergo surgery. The main goal …

This study tests a different dosing schedule of the chemotherapy drug capecitabine combined with the targeted therapy neratinib in people with advanced HER2-positive breast cancer. The goal is to find the safest dose that still works. About 34 adults with stage IV breast cancer t…

This Phase 2 trial is testing whether a combination of two targeted drugs (trastuzumab and pertuzumab) given as a single shot under the skin, along with standard hormone therapy, can prevent cancer from returning after surgery in people with early-stage, hormone receptor-positive…

This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer retu…

This study tests a combination of two targeted drugs, tucatinib and alpelisib, in people with a specific genetic mutation (PIK3CA) and HER2-positive advanced breast cancer. About 40 adults whose cancer has spread or cannot be removed will take these pills daily. The goal is to se…

This early-stage study tests the safety of tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancer that has worsened after standard treatments. Researchers will monitor side effects and how the drug moves through the body. The goal is to s…

This early-phase study planned to test whether injecting the seasonal flu vaccine directly into breast tumors could help the immune system attack the cancer. It was designed for women with triple-negative or HER2+ breast cancer who were already scheduled for chemotherapy before s…

This study tests an experimental drug called ARX788 in people with HER2-positive breast cancer that has spread and no longer responds to standard treatments. About 72 adults will receive the drug to see if it shrinks tumors and how long that effect lasts. The goal is to find a ne…

This early-phase trial tests whether adding a single, focused dose of radiation before surgery can make the immunotherapy drug pembrolizumab work better in people with early-stage breast cancer. About 27 participants will receive both treatments, then have surgery to see if the t…

This early-phase trial is testing a drug called DS-8201a in 62 adults with advanced HER2-positive solid tumors that have not responded to standard treatments. The drug works by attaching to the HER2 protein on cancer cells and damaging their DNA, which may kill the cells. Researc…

This phase II trial is testing a less intense chemotherapy regimen for people with early-stage HER2-positive breast cancer. The experimental treatment combines paclitaxel with two targeted drugs (trastuzumab and pertuzumab), skipping the harsher anthracycline drugs. Researchers w…

This phase 2 trial tests the safety and effectiveness of combining sacituzumab govitecan (Trodelvy) with trastuzumab (Herceptin) in 28 people with HER2+ metastatic breast cancer that has worsened after treatment with trastuzumab deruxtecan. The goal is to see how many participant…

This trial is testing whether giving a small dose of targeted radiation to a part of the breast tumor before standard chemotherapy can help the immune system fight the cancer more effectively. The study includes 40 people with high-risk or locally advanced breast cancer. After ra…

This phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 therapy and hormone therapy can help people with HR+/HER2+ metastatic breast cancer live longer without their cancer getting worse. About 518 participants who have already received initial treatmen…

This early-phase trial tests the safety of combining the targeted drug abemaciclib with various other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) in 198 people whose breast cancer has spread. The goal is to find safe combinations that may help control the…

This study tests a new combination of two drugs—niraparib and trastuzumab—in people with metastatic HER2-positive breast cancer, an aggressive form of the disease. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth. About 46 women with advanced ca…

This Phase 2 trial is testing a combination of two drugs—docetaxel (chemotherapy) and trastuzumab (a targeted therapy)—in 53 Nigerian women with HER2-positive breast cancer. The goal is to see how many women have no cancer left after treatment (called a complete response). The st…

This study tests whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab can completely eliminate HER2-positive breast tumors before surgery. About 113 women with early-stage HER2+ breast cancer will receive the combination, then have surgery to check …

This study follows 170 women with early-stage HER2+ breast cancer who are receiving the biosimilar drug Zedora after surgery. Researchers want to see how well it prevents the cancer from coming back and how safe it is in real-world settings, where patients may have other health i…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer before surgery. About 90 women with early-stage, operable breast cancer will ta…

This phase 3 trial tests whether a new drug called HS627 (a biosimilar) works as well as pertuzumab when given with trastuzumab and docetaxel before surgery for HER2-positive breast cancer. About 408 people with early-stage or locally advanced breast cancer took part. The main go…

This phase 2 trial tests whether a newer drug, margetuximab, combined with chemotherapy, works better than the standard trastuzumab combination for HER2-positive breast cancer before surgery. The study includes 174 people with stage II or III disease who have a specific genetic v…

This phase 2 trial is testing whether adding the drug tucatinib to standard treatments (pertuzumab and trastuzumab) can help people with HER2-positive metastatic breast cancer whose cancer has progressed in the brain after local therapy. About 53 participants will receive tucatin…

This early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …

This early-stage trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and pembrolizumab (an immunotherapy)—in about 115 adults with advanced breast or non-small cell lung cancer that has a specific marker called HER2. The study has two part…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This phase 3 trial tests whether the experimental drug DS-8201a (trastuzumab deruxtecan) works better than the current standard T-DM1 for people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. About 524 adults who have …

This Phase 3 trial compares a new drug called DB-1303 (also known as BNT323) to the current standard treatment T-DM1 in 228 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. All participants have already been treat…

This study was designed to test whether a biosimilar version of pertuzumab (EG1206A) works as well as the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either the biosimilar or the original dr…

This study aimed to see if giving less chemotherapy before surgery, followed by targeted therapy, could work well for women with early-stage HER2-positive breast cancer. It planned to enroll women with tumors at least 2 cm or lymph node involvement. However, the study was withdra…

This pilot study is testing whether women with HER2-positive breast cancer who respond well to initial chemotherapy can safely receive less treatment after surgery. About 100 participants will receive a combination of drugs (paclitaxel, trastuzumab, and pertuzumab) before surgery…

This phase 2 trial is testing whether doctors can safely reduce the amount of chemotherapy given to people with HER2-positive breast cancer by using imaging scans to guide treatment. The study involves 462 participants with stage II or III disease who receive a combination of dru…

This phase 2 trial is testing whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can eliminate more cancer in women with HER2-positive early breast cancer. About 53 participants will receive the combination, and the main goal is to …

This phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whos…

This Phase 3 trial tests whether a combination of targeted drugs (trastuzumab, alpelisib, and possibly fulvestrant) can work better than standard chemotherapy for people with a specific genetic mutation (PIK3CA) in HER2+ advanced breast cancer. The study enrolled 27 participants …

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This phase 1 trial tests whether a new radioactive imaging agent, 89Zr-ss-pertuzumab, is safe for detecting HER2-positive breast cancer in 60 participants. The agent is designed to bind to HER2 proteins on cancer cells and show up on PET/CT scans. The main goal is to check for si…

This pilot study tests a new type of breast scan called DBT-TOBI, which combines 3D mammography with light-based imaging. Researchers want to see if it can predict how well breast cancer responds to chemotherapy early in treatment. The study involves 30 women with HER2+ or triple…

This study tested whether a special PET scan using a radioactive tracer can predict how well patients with advanced HER2-positive breast cancer respond to the drug T-DM1. Ten women with cancer that had spread to other parts of the body received the scan before treatment. The goal…

This study explores whether routine brain MRIs and spinal taps can detect early signs of breast cancer spreading to the brain in people with HER2-positive breast cancer. Researchers will enroll 9 participants to see if these tests are feasible and well-tolerated. The goal is to c…

This phase 2 trial is testing whether a special PET scan using copper Cu64-DOTA-trastuzumab can predict how well HER2-positive breast cancer responds to trastuzumab and pertuzumab before surgery. The study involves 18 women with locally advanced HER2-positive breast cancer. The g…

This pilot study tests a special PET scan using a radioactive tracer called 64Cu-DOTA-trastuzumab in 18 women with advanced HER2-positive breast cancer. The goal is to see if this scan can better identify HER2-positive tumors compared to standard imaging. If it works, it may help…

This study looks at whether a breast MRI-guided biopsy can accurately tell if a woman's breast cancer has completely disappeared after chemotherapy. Researchers will enroll 31 women whose tumors are no longer visible on MRI after treatment. If the biopsy correctly identifies a co…

This study tests two different vaccines designed to prevent HER-2 positive breast cancer from coming back in people who have already completed initial treatment. About 119 participants who had surgery after chemotherapy will receive one of the two vaccines, followed by booster sh…

This study looks at whether the anti-nausea drug NEPA (netupitant/palonosetron) can prevent vomiting and nausea in people with advanced HER2-positive or HER2-low breast cancer who are receiving the drug T-DXd. It will follow 100 participants across multiple hospitals to see how w…

This study tests whether a less invasive ultrasound-guided biopsy can accurately tell if breast cancer has been completely wiped out by chemotherapy, compared to the standard method of checking during surgery. About 43 women with aggressive breast cancer types (triple negative or…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study was designed to see if a combination of PET and MRI scans could detect early signs that treatment is working in people with stage IV HER2-positive breast cancer. The plan was to scan participants up to three times over six months and compare the images to standard meas…

This study was designed to see if a blood test that looks for tiny pieces of tumor DNA (called ctDNA) could find leftover cancer cells in people with early-stage breast cancer after standard treatment. The goal was to help doctors decide who might need more therapy. However, the …

This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The …

This study looks at whether people with HER2-positive breast cancer can safely have fewer heart check-ups while on a specific type of treatment (trastuzumab without anthracyclines). About 190 participants will be followed to see if less monitoring leads to serious heart problems.…

This study looks at how the drug tucatinib enters and works in HER2+ cancers that have spread to the brain. Nine adults with breast, lung, or other cancers will take tucatinib before brain surgery. Researchers will test tumor samples to find genetic clues about why some cancers s…

This pilot study is testing whether a personalized blood test that looks for leftover tumor DNA can help doctors make better treatment decisions for people with early-stage breast cancer. About 34 participants with triple-negative or HER2-positive breast cancer will receive chemo…

This study follows 700 breast cancer patients to understand how chemotherapy affects the heart. Researchers use echocardiograms and blood tests to find early signs of heart damage. The goal is to better predict and prevent cardiotoxicity in cancer treatment.

This study looks at how the tumor microenvironment changes during chemotherapy in 30 patients with HER2-positive breast cancer. Researchers will take samples before, during, and after treatment to see what happens at the cellular level. The goal is to better understand how chemot…

This study follows 36 people with HER2-positive breast cancer who are receiving the drug T-DM1. Researchers want to learn how often and how severely the drug causes nerve damage (peripheral neuropathy), such as numbness, tingling, or pain. Participants will report their symptoms …

This study looks at how well a cardiopulmonary exercise test (CPET) can measure oxygen use in women with HER2-positive breast cancer who have mild heart problems from their cancer treatment. The goal is to see if this test can help predict how their heart and lungs will handle co…